Showing results (1751-1760 of 1,843) with videos related to

Sort By:
Pageof 185
The European Respiratory Journal|March 17, 2018
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm studySandrine Loubière, Alexandre Drezet, Michèle Beau-Faller, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2018
Development of autotaxin inhibitors: A series of zinc binding triazolesChristopher G Thomson, Darren Le Grand, Mark Dowling, et al.
Cancer Medicine|May 31, 2018
SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patientsCamille Emprou, Pauline Le Van Quyen, Jérémie Jégu, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING studyElisabetta Petracci, Luigi Pasini, Milena Urbini, et al.
JTO Clinical and Research Reports|September 30, 2021
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation SubtypesAnne-Marie Ruppert, Michèle Beau-Faller, Didier Debieuvre, et al.
Nucleic Acids Research|June 15, 2013
Whole-body scanning PCR; a highly sensitive method to study the biodistribution of mRNAs, noncoding RNAs and therapeutic oligonucleotidesJulien A Boos, David W Kirk, Mari-Luz Piccolotto, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohortAurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2022
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800AKaren L Reckamp, Mary W Redman, Konstantin H Dragnev, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
Oncoimmunology|May 17, 2017
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapyHélène Roussel, Eléonore De Guillebon, Lucie Biard, et al.
Pageof 185